Corporate India is starting to step up its capital expenditure plans amid government incentives and signs of rising demand, company executives and analysts have indicated. Illustration: Uttam......
Taking their cue from Cipla and Alembic, many in the pharmaceutical industry have challenged the new drug price fixation orders that were to be implemented from July 29. The move is expected to......
A common 'ethical marketing practices code' for drug makers in the country is unlikely in the near future despite the latest attempts of the government's department of pharmaceuticals to evolve......
A segment of drug companies such as tablet and capsule makers may benefit from the government's move to review polluting status of these companies, which may help them save costs on pollution......
The country's leading drug makers, including Ranbaxy Laboratories, Cipla, Cadila Pharmaceuticals, Nicholas Piramal and Wockhardt, will soon withdraw about 60 drug combinations from the market. The......